Image
Image
LOGO

Puja and Samir Kaul Professorship of Biomedical Innovation and Translation

Image
Image

August 2026

Benefactor Report

Table of Contents

Image
Image

01.

Letter from Dean Daley 

02.

Professorship Update

 

Image

03.

Research Fund Update

 

Image

Table of Contents

Image

Therapeutics Initiative

02.

TOC button - 1 Page 2

Corporate Alliances

03.

TOC button - 1 page 3

Letter from the Dean

01.

TOC button - 1 Page 1

Blavatnik Harvard Life Lab Longwood

04.

TOC button - 1 page 4

Therapeutics Education
(continued)

08.

TOC button - 1 page 7
Image

Blavatnik Therapeutics
Challenge Awards

06.

TOC button - 1 page 5

Therapeutics Education

07.

TOC button - 1 page 6

Q-FASTR

05.

TOC button - 1 page 4
Image
Image
Image
Image

Thank you from Dean Daley

August 4, 2026
Dear Puja and Samir,
I’m pleased to share this year’s update on the Puja and Samir Kaul Professorship of Biomedical Innovation and Translation. Your support empowers Mark Namchuk to lead the HMS Therapeutics Initiative, integrating translational science into the core mission of Harvard Medical School and reshaping how we partner with industry and investors to accelerate the translation of academic discoveries into patient care.
Sincerely,
George Q. Daley, MD, PhD 
George Q. Daley, MD, PhD | Dean of the Faculty of Medicine | Caroline Shields Walker Professor of Medicine
25 Shattuck Street, Boston, MA 02115 | t: (617) 432-1501 | e: George_Daley@hms.harvard.edu
Image
Over the past year, Mark has advanced a comprehensive strategy to strengthen HMS’s therapeutic ecosystem. The Therapeutics Initiative has defined a redesigned approach to biopharma collaborations, supported early-stage discovery through Q-FASTR and the relaunch of the Blavatnik Therapeutics Challenge Awards, and expanded a robust pipeline of talent through the its education initiatives.
Dean's Photo
Next →
Dean's Flag with link to bio
George Q. Daley, MD, PhD
Thank you for your generosity and continued partnership. Your vision and commitment help drive the translation of scientific breakthroughs into therapies and prepare the leaders who will carry this work forward. Mark and I look forward to seeing you both again soon.
Image
Image
Image

 Puja and Samir Kaul Professorship of Biomedical Innovation and Translation

​Dr. Mark Namchuk is the Puja and Samir Kaul Professor of the Practice of Biomedical Innovation and Translation in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, where he is also the Executive Director of Therapeutics Translation and the Academic Director of the Master of Medical Sciences in Therapeutic Sciences program.   

Namchuk headshot
Namchuk banner
Mark Namchuk, PhD

Dr. Namchuk oversees every aspect of the HMS Therapeutics Initiative as its executive director, from developing corporate alliances to guiding the Blavatnik Harvard Life Lab Longwood and advancing therapeutics education programs. Over the past year, the significant challenges facing the HMS research enterprise have shaped the goals and aspirations of the Therapeutics Initiative. This year’s work focused on integrating translational science into HMS's mission. While the drive to build financial resilience motivates this effort, it also creates an opportunity to reshape relationships with commercial organizations and to integrate academic and industrial science, with the goal of accelerating the impact of academic discoveries on patients.

 

To advance this work, HMS is developing distinct strategies for collaborations with established industry and with the venture investment community. In late 2025, the HMS Academic Committee of Research Sustainability commissioned a task force, led by Dr. Namchuk, to examine how collaborations with established industry should be structured to best support HMS’s academic missions of scholarly research and training, and to establish these collaborations more quickly. The task force issued its final report in March 2026.

    The Therapeutics Initiative

    Image

    Read more about the Therapeutics Initiative

    Next →

    Therapeutics Initiative

    Image
    Image
    Image

     Puja and Samir Kaul Professorship of Biomedical Innovation and Translation

    Corporate Alliances

    In 2020, HMS and the global pharmaceutical company AbbVie Inc. forged a $30 million collaborative research alliance and launched a multipronged effort at HMS to study and develop novel therapies against emergent viral infections, focusing on coronaviruses and viruses that cause hemorrhagic fever. This partnership concluded in 2026 but provided a template for future alliances.

     

    Over the past year, HMS has significantly expanded its corporate alliances, applying the recommendations from the task force report. These alliances center on basic research questions rather than pipeline-driven activities.

     

    HMS is currently engaged in seven active discussions with different biopharma partners and intends to finalize these deals in 2026. In addition, HMS signed an agreement with Northpond Ventures to support potential investment in very early-stage, therapeutics-oriented projects at HMS aimed at company creation. This agreement includes a $1 million gift to fund a Northpond postdoctoral fellowship program, with one fellow selected for a two-year fellowship each year for five years. 

      Corporate Alliances

      Harvard University expands multifaceted research alliance with Northpond Labs to advance solutions in healthcare

      Click to Read →
      Next →
      ← Previous

      The Wyss Institute’s alliance with Northpond Labs supports early-stage, transformative research with strong translation potential. Hear Northpond Ventures co-founders Michael Rubin and Sharon Kedar explain why they decided to partner with the Wyss, as well as the leaders of various Wyss projects and startups about how support from Northpond has helped accelerate their technologies to the market. Credit: Wyss Institute at Harvard University

      Image
      Image
      Image

       Puja and Samir Kaul Professorship of Biomedical Innovation and Translation

      Blavatnik Harvard Life Lab Longwood

      • Provides wet lab and co-working space for early-stage biotech and life science startups led by Harvard students, alumni, faculty, and postdocs.

      • Since October 2022: 12 startups incubated, ~80% capacity maintained.
      • Recent exit: Cellular Intelligence (formerly Somite), an AI–stem cell company founded by three HMS faculty members.
      • January 2026 flood significantly damaged wet lab space and displaced 10 teams.
      • Temporary lab space was rapidly constructed to support displaced teams.
      • The Life Lab is currently closed for restoration with reopening planned for early August 2026.

       

        Blavatnik Harvard Life Lab Longwood

        Combining Biology and AI To
        Advance Cell Therapy

        Click to Read →
        ← Previous
        Next →
        Image
        Image
        Image

         Puja and Samir Kaul Professorship of Biomedical Innovation and Translation

        Q-FASTR

        The Quadrangle Fund for Advancing and 
        Seeding Translational Research

        232 grant proposals reviewed

        7 new startups

        54% of HMS eligible
        faculty applied

        $349M in follow-on
        funding

        Image

        221 researchers engaged

        53 patents

        21 publications

        100 total projects

        In 2025, Q-FASTR ran two funding rounds and supported two cohorts of awardees, including distinguished researchers from HMS, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Brigham and Women’s Hospital. Through its ongoing efforts, Q-FASTR continues to accelerate research and development, fueling advances with the potential to reshape the future of medicine.​

        Inspiring a new wave of support
        for translational science

        Click to Read →
        Next →
        ← Previous

        Since 2016

        Image
        Image
        Image

         Puja and Samir Kaul Professorship of Biomedical Innovation and Translation

        Blavatnik Therapeutics Challenge Awards

        7 proposals selected
        for full review

        3 new awards

        68 proposals

        2026

        20 projects funded

        13 projects completed

        6 completed projects yielded a clinical candidate, license, or startup

        2020-2024

        2 completed projects in active business discussions

        Next →
        ← Previous

        Blavatnik Therapeutics Challenge Awards

        Additional support from the Blavatnik Family Foundation enabled HMS to relaunch the Blavatnik Therapeutics Challenge Awards and to offer urgent funding to help early-career researchers affected by federal funding disruptions.

        Image
        Image
        Image

         Puja and Samir Kaul Professorship of Biomedical Innovation and Translation

        Therapeutics Education Programs

        Cohort size increased 412% since 2012

        96 alumni (2025-2026)

        145 active students (2025-2026)

        Scale and Growth

        94.5% retention rate

        77 companies

        Therapeutics Graduate Program

        The Therapeutics Graduate Program (TGP) is a university-wide PhD certificate program for Harvard graduate students in any life science doctoral program. The program is led by two dedicated faculty directors: David Golan, AB ’75, MD, PhD, dean for research initiatives and global programs, the George R. Minot Professor of Medicine, and a professor of biological chemistry and molecular pharmacology at HMS; and Timothy Mitchison, PhD, the Hasib Sabbagh Professor of Systems Biology at HMS. 

        Career outcomes

        • 24% of alumni in academia.

        • 31% in industry R&D.

        • 45% in other therapeutics sectors (VC, consulting, business development, regulatory science, etc.). 

        Curriculum and community

        • July 2025: updated curriculum to reflect industry changes, reduce redundancy, and enhance academic experience.

        • New core course in cell and gene therapies, the first of its kind at Harvard, taught by Fernando Camargo, PhD and Irene Wong, PhD ’24.

        • Program manager John Kropowensky, MEd advises on courses, internships, and careers.

        • Annual symposium (record turnout in 2025–2026) plus multiple academic and career development panels. 

        Master of Medical Sciences in Therapeutic Sciences

        In April 2025, the Master of Medical Sciences (MMSc) in Therapeutic Sciences program enrolled its first cohort of 15 students. The Department of Biological Chemistry and Molecular Pharmacology in the Blavatnik Institute at HMS serves as the program’s academic home. The program trains individuals to become professional experimentalists in early drug discovery and prepares them to lead in high-need areas of therapeutic sciences in both the biopharmaceutical industry and academia. Dr. Namchuk serves as the inaugural faculty director and Stephen Blacklow, AB ’83, MD ’91, PhD ’91, the Gustavus Adolphus Pfeiffer Professor of Biological Chemistry and Molecular Pharmacology and chair of the department, serves as co-director.

        The inaugural cohort has completed its classroom requirements and has matched with faculty labs across HMS. Admissions for the 2027 cohort have closed; the admissions committee reviewed 99 applications and extended 16 offers in the last week of April. 

        ← Previous
        Next →
        Image
        Image
        Image

         Puja and Samir Kaul Professorship of Biomedical Innovation and Translation

        Therapeutics Education Programs

        671 need statements

        326 clinical observations

        2025–2026 Highlights

        250+ stakeholders engaged

        Image
        • Advancing three priority opportunities:
          1. Consolidating appointments for oncology patients needing multidisciplinary care.
          2. Improving nutrition intake for older patients on dysphagia diets
          3. Safely mobilizing older patients after hip fracture surgery.
        • Applied for six external grants/accelerators; won the Harvard School of Public Health Design Thinking Challenge.

        • Multidisciplinary oncology appointment project has strong support from Mass General Brigham Cancer Institute leaders and is moving toward a pilot agreement with the genitourinary multidisciplinary clinic.

        • Seeking funding to support two fellows to continue working full time on this project after the fellowship.
        ← Previous
        Next →

        HealthTech Fellowship Program

        • ​10-month, full time program training cross disciplinary teams in health technology innovation using the biodesign process.

        • The program, which has been operating for five years, became a part of the Therapeutics Initiative this year following the reorganization of the Center for Primary Care. 
        • Led by Paola Abello, MBA.

        2025–2026 Cohort and Focus

        Partner: MGH Center for Aging and Serious Illness,
        Hosted by: Christine Ritchie, MD, MPH and Caroline Meehan, MD

        Melinda Hu headshot
        Caitlyn Loo headshot
        Sabrina Ramnarine headshot

        Melinda Hu is a startup operator and healthcare innovator who is passionate about leveraging technology to improve equity and access in overlooked areas. She was the first marketer at Photon Health, helping to enhance medication access, and previously, she drove growth at the women’s health startup Elix. 

        Emily Huang, MD, is a urology chief resident at Houston Methodist Hospital and incoming urologic oncology fellow at MGH. A Dallas native, she studied biochemistry and global health technologies at Rice University, where she developed patient education tools like a diabetic foot ulcer simulator.

        Caitlyn Loo is a clinician, scientist, and healthtech innovator dedicated to transforming healthcare through technology, policy, and investment. Originally from Singapore, she studied medicine at the Royal College of Surgeons in Ireland, where she founded several initiatives and received leadership awards.

        Sabrina Ramnarine, PhD is a physician-scientist and clinical research fellow at Guy’s and St Thomas’ NHS Foundation Trust, as well as an honorary senior lecturer at King’s College London. An NHS clinical entrepreneur, she holds a BSc from the University of St. Andrews, an MBChB from the University of Edinburgh, and completed postgraduate training at Oxford.

        Emily Huang
        Image
        Image

        Thank you !